Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira ®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
REFLECTIONS B538 –02 is a randomized, double-blind comparative study of the adalimumab (ADL) biosimilar PF-06410293, (ADL-PF), and reference ADL sourced from the European Union (ADL-EU) in patients with active ...
Source: Arthritis Research and Therapy - Category: Rheumatology Authors: Roy M. Fleischmann, Daniel F. Alvarez, Amy E. Bock, Carol Cronenberger, Ivana Vranic, Wuyan Zhang and Rieke Alten Tags: Research article Source Type: research